Elevated Levels of Active GSK3β in the Blood of Patients with Myotonic Dystrophy Type 1 Correlate with Muscle Weakness
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262110760 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Katherine Jennings und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Cincinnati Children's Hospital, 3333 Burnet Ave., Cincinnati, OH 45229, USA. Hauptthemen laut MEDLINE: Myotonic Dystrophy, Glycogen Synthase Kinase 3 beta, Muscle Weakness. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NINDS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Myotonic Dystrophy type 1 (DM1) is a complex disease affecting multiple tissues, including skeletal and cardiac muscles, the brain and the eyes. DM1 results from an expansion of CTG repeats in the 3′ UTR of the DMPK gene. Previously, we described that the small-molecule inhibitor of GSK3β, tideglusib (TG), reduces DM1 pathology in DM1 cell and mouse models by correcting the GSK3β-CUGBP1 pathway, decreasing the mutant CUG-containing RNA. Respectively, clinical trials using TG showed promising results for patients with congenital DM1 (CDM1). The drug development in DM1 human studies needs specific and noninvasive biomarkers. We examined the blood levels of active GSK3β in different clinical forms of DM1 and found an increase in active GSK3β in the peripheral blood mononuclear cells (PBMCs) in patients with CDM1, juvenile DM1 and adult-onset DM1 vs. unaffected patients. The blood levels of active GSK3β correlate with the length of CTG repeats and severity of muscle weakness. Thrombospondin and TGFβ, linked to the TG-GSK3β pathway in DM1, are also elevated in the DM1 patients’ blood. These findings show that the blood levels of active GSK3β might be developed as a potential noninvasive biomarker of muscle weakness in DM1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neurology, Cincinnati Children's Hospital, 3333 Burnet Ave., Cincinnati, OH 45229, USA.
- Department of Pediatrics, University of Cincinnati, 2600 Clifton Ave., Cincinnati, OH 45221, USA.
- Department of Surgery, Cincinnati Children's Hospital, 3333 Burnet Ave., Cincinnati, OH 45229, USA.
- Department of Neurology, Friedrich-Baur-Institute, LMU Clinics, Ludwig-Maximilians-University, Ziemssenstr., 80336 Munich, Germany.
- Department of Neurology & Rehabilitation Medicine, University of Cincinnati, 260 Stetson St., Cincinnati, OH 45219, USA.
ORCID-Profile: Cuixia Tian, Rebeccah L Brown, Paul S Horn, Benedikt Schoser, Hani Kushlaf
Förderung
- NIAMS NIH HHS
- NINDS NIH HHS
- NIH HHS
- Cincinnati Children’s Hospital Research Development Funds
Zitieren
APA
Jennings, K., Tian, C., Brown, R. L., Horn, P. S., Schoser, B., Kushlaf, H., Timchenko, N. A., & Timchenko, L. (2025). Elevated Levels of Active GSK3β in the Blood of Patients with Myotonic Dystrophy Type 1 Correlate with Muscle Weakness. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110760
Vancouver
Jennings K, Tian C, Brown RL, Horn PS, Schoser B, Kushlaf H, et al. Elevated Levels of Active GSK3β in the Blood of Patients with Myotonic Dystrophy Type 1 Correlate with Muscle Weakness. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110760
BibTeX
@article{Jennings2025,
author = {Jennings, Katherine and Tian, Cuixia and Brown, Rebeccah L and Horn, Paul S and Schoser, Benedikt and Kushlaf, Hani and Timchenko, Nikolai A and Timchenko, Lubov},
title = {Elevated Levels of Active GSK3β in the Blood of Patients with Myotonic Dystrophy Type 1 Correlate with Muscle Weakness},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262110760}
}
EUVIMED